Retatrutide vs Tirzepatide 2026: Triple Agonist vs Mounjaro Compared for Vietnam Buyers

You have been on tirzepatide for eight months in HCMC. The first stretch came off fast. The last few kilos have taken twice as long. You have hit the plateau everyone warned you about, and now a friend in the expat health group keeps mentioning retatrutide. He says the switch restarted his loss. You want to know if it is worth the upgrade, or if you should just push through on tirzepatide.

This is the actual question people are asking. Not the clinical-journal version. The practical, I-live-in-Vietnam, I-source-both-compounds version. This guide answers that.

Both drugs work. Both have a following in Vietnam, and both reach people here as research-grade vials rather than pharmacy pens. The real question is which one fits your situation, and where the tradeoffs actually matter. Let's get into it.

Quick Comparison

The Short Answer for Vietnam Buyers

How They Work

Tirzepatide and retatrutide belong to the same broad class (incretin mimetics) but activate a different number of receptors. Tirzepatide hits two. Retatrutide hits three. That one extra receptor changes the whole metabolic profile of the drug.

GLP-1 and GIP (the two receptors tirzepatide targets) primarily work on appetite and insulin response. They signal satiety to the brain, slow gastric emptying so you feel full longer, and improve glucose disposal. The weight loss is driven almost entirely by eating less. Tirzepatide does not directly change how much energy your body burns at rest.

Retatrutide adds the glucagon receptor. Glucagon in this context is not the blood sugar rescue hormone most people know. When pulsed chronically through a peptide drug, glucagon activates hepatic (liver) fat oxidation, increases basal metabolic rate, and shifts the body toward burning stored fat as fuel even at rest. That third receptor is the proposed mechanism behind the weight loss averages reported in the retatrutide trial. Because the two compounds have never been compared in the same trial, the real size of any difference between them is unknown.

Sources: Jastreboff et al., NEJM 2023 (retatrutide Phase 2), SURMOUNT-1 NEJM 2022, TRIUMPH-1 trial registration.

Weight Loss Results Compared

Tirzepatide results come from Phase 3 data, the SURMOUNT trial program, which is the gold standard for obesity drug evidence. Retatrutide results are Phase 2 data (Jastreboff et al., NEJM 2023), with Phase 3 (TRIUMPH) still in progress through 2026. That is why the 72-week retatrutide row below says "pending." TRIUMPH-1 primary outcomes are expected to read out in late 2026 or early 2027.

The two columns are not a head to head. Retatrutide and tirzepatide have never been studied in the same trial, so the figures above are drawn from separate programs with different populations, designs, and endpoints, lined up here for reference rather than as a contest. Nothing in that table establishes that one compound beats the other.

Individual variation is large on both drugs. Every trial in this class reports low responders who stall well short of the average and high responders who go well past it, and this page does not put a share of the population on either group. The numbers in the table are means, not guarantees, and a mean says nothing about where any one person lands.

Community reports from Vietnam expats broadly echo the shape of the trial data, but they are not data. People who switch compounds after a plateau sometimes report that loss restarts for a while, and people starting fresh often describe a fast early phase. This page does not attach numbers to those reports, because there are none measured under any protocol worth attaching.

Side Effects: Real-World Comparison

Side effects are the number one reason people quit GLP-1 drugs, not efficacy.⁵ Tirzepatide and retatrutide share most of the same side effects.⁶ Here is the honest breakdown, including the parts this page will not put a number on.

GI effects (nausea, diarrhea, constipation). Gastrointestinal effects are the most commonly reported side effects for both compounds, with nausea the most frequent of them. This page does not publish incidence rates for either: the two were studied in separate trials with different populations, designs, and reporting conventions, so the rates are not comparable across them, and quoting one against the other would invent a comparison that no trial has made. In both trial and community reports, these effects are described as most intense early on and easing from there.

Injection site reactions. Minor redness or itching at the injection site is an uncommon but recognised complaint on either compound, and it is usually a technique issue rather than the compound itself. The specifics of technique are something to learn from a physician or another qualified source. Reactions almost always resolve within 24 hours.

Heart rate. Both compounds reported small mean increases in heart rate in their trial data, and a mean increase is also noted on the approved tirzepatide labelling, so this is not a point of difference between them.⁷ The reported sizes come from separate trials and are not comparable across them, which is why no numbers are quoted here. If you have an underlying heart condition, or you track heart rate on a wearable and see a change, that belongs in front of a physician rather than being weighed up on a web page.

Gallbladder risk. Both drugs carry an elevated gallstone risk that scales with total weight loss. Users losing over 20 percent of body weight have measurably higher gallstone incidence regardless of compound.⁸ If you have a history of gallbladder issues, discuss with a physician before starting either.

Muscle loss. Any rapid weight loss drug carries a muscle loss concern. Retatrutide's more aggressive fat oxidation profile amplifies this if protein intake and resistance training are neglected. How much of each you need is worth setting with a physician or a qualified coach who has your numbers in front of them, rather than copying a generic target off the internet.

Micronutrient monitoring. Both drugs reduce food intake significantly, which can lead to B12, iron, and vitamin D deficiencies over months of use. Periodic bloodwork is worth arranging with a physician, especially on retatrutide where caloric intake drops harder in the first phase.

For more on what people do to blunt GI side effects on either drug, see the GLP-1 side effects management guide.¹⁵

What the Evidence Covers for Each Compound

The three cards below record what the published trial evidence and the Vietnam access picture cover for each compound. None of them is a recommendation. Whether any compound is appropriate for a specific person is a question for a licensed prescriber who has that person's history in front of them.

Dosing Comparison

This page does not publish dose amounts, escalation steps, or a week-by-week schedule for either compound. What follows is the regulatory difference between the two, not guidance on how either one is used.

That difference is entirely regulatory. Tirzepatide has an approved label, with a defined path set out behind it by regulators and a prescriber to interpret it.¹² Retatrutide has no approved label anywhere, only trial protocols, so its dosing is still being worked out while the drug sits in Phase 3. In plain terms, one of these compounds has an official answer to the dosing question and the other does not, which is precisely why the answer for any individual belongs with a licensed prescriber rather than a page like this one.

Plateaus happen on both compounds, and they usually reflect adaptive metabolic slowdown rather than a failure of the drug. What to do about one, including whether anything about the dose should change at all, is a conversation for a qualified prescriber, not a decision to take from a web page.

Vietnam-Specific Considerations

This section is why this guide exists. Most comparison articles online are written for US or UK readers. Here is what actually matters if you are buying either drug in Vietnam.

Access. Mounjaro (tirzepatide) holds no Vietnamese marketing registration, so no pharmacy here dispenses it and the research-grade route is the one that exists. Retatrutide is research-grade only. No pharmacy in Vietnam stocks retatrutide, and there is no registered product for it here to stock.

Pricing breakdown in VND. Branded Mounjaro and Zepbound hold no Vietnamese marketing registration, so there is no registered pharmacy price to quote for tirzepatide.¹³ For research-grade supply, the figures this page can point to are the two listings on the community supply index: retatrutide at 5,200,000 VND, about $205, and tirzepatide at 4,700,000 VND, about $185. Both are listing prices only. Neither states a quantity, a vial size or a period, so neither is a monthly total and neither supports a per milligram comparison between the two. This page publishes no per vial range, because no source cited here states one. How long any vial lasts is a clinical question, not something this page will put a number on.

Cold chain considerations. HCMC and Hanoi summer temperatures regularly hit 35 to 40 Celsius. Both compounds require refrigeration between 2 and 8 Celsius. Shipping with gel packs in insulated packaging is non-negotiable. Unreconstituted retatrutide is slightly more heat-stable in lyophilized form than reconstituted tirzepatide in solution, but neither will survive a day in a hot car or a non-refrigerated hotel mini-fridge. Always request express shipping during Vietnamese summer.

Customs considerations. Research-grade compounds shipped from international suppliers (China, EU, US) cross customs on entry. This page makes no prediction about how any given shipment is treated, and nobody should read someone else's uneventful delivery as a rule. Domestic Vietnamese suppliers do not cross a border at all, which is one reason many people here use them. Full legal context is in the peptide legality guide.

Physician oversight. There is no registered pharmacy route for tirzepatide in Vietnam, so both compounds on this page reach you research-grade, and both are worth baseline labs before you start. FV Hospital and Vinmec in both cities have endocrinologists who understand GLP-1s and can run those labs and monitor you. The HCMC peptide guide and Hanoi peptide guide cover physician options in each city.

Why people usually meet tirzepatide first. The common pattern in the Vietnam expat community is that tirzepatide is the first of the two people encounter, and the reason is history rather than strategy. It has been around longer, it is far more widely used, and its research-grade listing on the supply index sits below the retatrutide one, though neither listing states a quantity. If tirzepatide works well and results are sufficient, people stay there. Whether to change compound at all, and when, is a prescriber's call, not a community default.

The Verdict

The table below sorts this guide's comparison by goal, so the trial data and the Vietnam supply picture can be read one line at a time. It records what the evidence points to for each goal rather than what any one reader should take: appropriateness for a specific person remains a question for a licensed prescriber.

Both compounds have real evidence behind them, which is why the table splits by goal instead of naming one winner: the trade-offs run in different directions, weight-loss magnitude against length of safety record, and access route against approval status. The magnitude column rests on figures from separate trials, never a head to head, so read it as where the published evidence sits rather than as a contest one compound won. For a deeper clinical view, this side-by-side comparison of the two compounds lines up the trial data point by point.

What Vietnam Users Report

The following patterns come from community reports in Vietnam expat health groups through 2025 and 2026. These are anecdotal, not clinical claims.

The most consistent pattern reported is the tirzepatide to retatrutide switch. People who plateau on tirzepatide and later move to retatrutide often report that loss restarts for a period. No figures are attached to that here: community reports are not measured under any protocol, and the numbers people quote to each other are not evidence of anything.

The second pattern is how the early weeks feel. Many first-time retatrutide users describe more intense nausea and appetite loss early on than they remember from tirzepatide, easing after the first stretch. People who switched often call retatrutide "more noticeable" rather than "worse." Those are impressions rather than measurements, and since the two compounds have never been studied in the same trial, there is nothing to check them against.

The third pattern is cost. Retatrutide lists above research-grade tirzepatide on the supply index, and people weigh that against how each one has worked for them. This page will not put a total on a weight loss journey. That depends on the individual, how long they stay on anything, and clinical decisions that are not ours to make.

Availability in Vietnam

Frequently Asked Questions